Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, typically as adjunctive therapy when seizure control is not achieved with other agents. The medication is formulated to provide consistent plasma concentrations and is marketed within the European Union.

GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and healthcare institutions across multiple regions.

Lacosamide is an anticonvulsant that targets focal seizure activity in epilepsy.

Partial‑onset seizures: provides adjunctive reduction of seizure frequency in patients whose seizures are not fully controlled by existing antiepileptic regimens, improving overall seizure management. Focal epilepsy: enhances overall seizure control when combined with other antiepileptic medications, contributing to better management of focal seizure disorders and reducing the burden of breakthrough seizures. Adjunctive therapy for epilepsy: serves as an add‑on option for individuals with epilepsy requiring additional seizure suppression beyond monotherapy, supporting clinicians in achieving target seizure control.

Lacosamide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of queasiness or urge to vomit. - Fatigue: persistent tiredness not relieved by rest. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation that may affect heart rhythm. - Suicidal thoughts or behavior: emergence of depressive symptoms or self‑harm ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Lacosamide, clinicians should consider several safety aspects.

Renal impairment: assess renal function and consider dose adjustment if required. Pregnancy: safety not established; use only if potential benefit justifies potential risk to fetus. Concomitant CNS depressants: monitor for additive sedation or dizziness. Cardiac disease: evaluate ECG for PR interval changes before initiating therapy. Alcohol consumption: advise patients to limit alcohol as it may increase dizziness. Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide effectiveness. - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): increased risk of CNS depression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): possible increased bleeding tendency. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy; advise alternative methods. - Warfarin: monitor INR as lacosamide may affect anticoagulation control.